
BNTC Stock Forecast & Price Target
BNTC Analyst Ratings
Bulls say
Benitec Biopharma Inc. is positioned favorably due to the promising results from its ongoing clinical trials for BB-301, which indicate a potential for accelerated regulatory pathways and premium pricing opportunities based on the therapy's value proposition. The company has reported a 100% responder rate among participants, alongside evidence of sustained clinical improvement in swallowing capabilities, raising the probability of approval to 45%. Financially, Benitec Biopharma's robust balance sheet, with $94.5 million in cash, indicates strong capital support for the continued development of BB-301, enhancing the company's prospects for success in pivotal clinical assessments.
Bears say
Benitec Biopharma reported a net loss of $0.21 per share for F1Q26, which was an improvement compared to the forecasted $0.41 loss, primarily affected by a higher-than-expected number of shares outstanding. Despite this adjustment, the company faces substantial risks, including the possibility of slower-than-expected progress in clinical trials for its lead candidate BB-301, negative trial data, challenges in obtaining regulatory approval, and potential market uptake issues. Furthermore, projected losses for fiscal 2026 remain significant at $1.00 per share, highlighting concerns regarding long-term viability and potential equity dilution risks.
This aggregate rating is based on analysts' research of Benitec Biopharma Limited Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
BNTC Analyst Forecast & Price Prediction
Start investing in BNTC
Order type
Buy in
Order amount
Est. shares
0 shares